Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Lungu, Adrian (35812503300)"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Is there a dominant-negative effect in individuals with heterozygous disease-causing variants in COL4A3/COL4A4?
    (2024)
    Riedhammer, Korbinian M. (57200625458)
    ;
    Simmendinger, Hannes (57897933000)
    ;
    Tasic, Velibor (7003911066)
    ;
    Putnik, Jovana (14008113300)
    ;
    Abazi-Emini, Nora (57896737400)
    ;
    Stajic, Natasa (6602606131)
    ;
    Berutti, Riccardo (24483074500)
    ;
    Weidenbusch, Marc (44961542100)
    ;
    Patzer, Ludwig (6601983901)
    ;
    Lungu, Adrian (35812503300)
    ;
    Milosevski-Lomic, Gordana (20436011000)
    ;
    Günthner, Roman (6507490502)
    ;
    Braunisch, Matthias C. (57192699344)
    ;
    Ćomić, Jasmina (57896737200)
    ;
    Hoefele, Julia (57196082805)
    Alport syndrome (AS) shows a broad phenotypic spectrum ranging from isolated microscopic hematuria (MH) to end-stage kidney disease (ESKD). Monoallelic disease-causing variants in COL4A3/COL4A4 have been associated with autosomal dominant AS (ADAS) and biallelic variants with autosomal recessive AS (ARAS). The aim of this study was to analyze clinical and genetic data regarding a possible genotype–phenotype correlation in individuals with disease-causing variants in COL4A3/COL4A4. Eighty-nine individuals carrying at least one COL4A3/COL4A4 variant classified as (likely) pathogenic according to the American College of Medical Genetics guidelines and current amendments were recruited. Clinical data concerning the prevalence and age of first reported manifestation of MH, proteinuria, ESKD, and extrarenal manifestations were collected. Individuals with monoallelic non-truncating variants reported a significantly higher prevalence and earlier diagnosis of MH and proteinuria than individuals with monoallelic truncating variants. Individuals with biallelic variants were more severely affected than those with monoallelic variants. Those with biallelic truncating variants were more severely affected than those with compound heterozygous non-truncating/truncating variants or individuals with biallelic non-truncating variants. In this study an association of heterozygous non-truncating COL4A3/COL4A4 variants with a more severe phenotype in comparison to truncating variants could be shown indicating a potential dominant-negative effect as an explanation for this observation. The results for individuals with ARAS support the, still scarce, data in the literature. © 2024 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Is there a dominant-negative effect in individuals with heterozygous disease-causing variants in COL4A3/COL4A4?
    (2024)
    Riedhammer, Korbinian M. (57200625458)
    ;
    Simmendinger, Hannes (57897933000)
    ;
    Tasic, Velibor (7003911066)
    ;
    Putnik, Jovana (14008113300)
    ;
    Abazi-Emini, Nora (57896737400)
    ;
    Stajic, Natasa (6602606131)
    ;
    Berutti, Riccardo (24483074500)
    ;
    Weidenbusch, Marc (44961542100)
    ;
    Patzer, Ludwig (6601983901)
    ;
    Lungu, Adrian (35812503300)
    ;
    Milosevski-Lomic, Gordana (20436011000)
    ;
    Günthner, Roman (6507490502)
    ;
    Braunisch, Matthias C. (57192699344)
    ;
    Ćomić, Jasmina (57896737200)
    ;
    Hoefele, Julia (57196082805)
    Alport syndrome (AS) shows a broad phenotypic spectrum ranging from isolated microscopic hematuria (MH) to end-stage kidney disease (ESKD). Monoallelic disease-causing variants in COL4A3/COL4A4 have been associated with autosomal dominant AS (ADAS) and biallelic variants with autosomal recessive AS (ARAS). The aim of this study was to analyze clinical and genetic data regarding a possible genotype–phenotype correlation in individuals with disease-causing variants in COL4A3/COL4A4. Eighty-nine individuals carrying at least one COL4A3/COL4A4 variant classified as (likely) pathogenic according to the American College of Medical Genetics guidelines and current amendments were recruited. Clinical data concerning the prevalence and age of first reported manifestation of MH, proteinuria, ESKD, and extrarenal manifestations were collected. Individuals with monoallelic non-truncating variants reported a significantly higher prevalence and earlier diagnosis of MH and proteinuria than individuals with monoallelic truncating variants. Individuals with biallelic variants were more severely affected than those with monoallelic variants. Those with biallelic truncating variants were more severely affected than those with compound heterozygous non-truncating/truncating variants or individuals with biallelic non-truncating variants. In this study an association of heterozygous non-truncating COL4A3/COL4A4 variants with a more severe phenotype in comparison to truncating variants could be shown indicating a potential dominant-negative effect as an explanation for this observation. The results for individuals with ARAS support the, still scarce, data in the literature. © 2024 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The multifaceted phenotypic and genotypic spectrum of type-IV-collagen-related nephropathy—A human genetics department experience
    (2022)
    Ćomić, Jasmina (57896737200)
    ;
    Riedhammer, Korbinian M. (57200625458)
    ;
    Günthner, Roman (6507490502)
    ;
    Schaaf, Christian W. (59886124500)
    ;
    Richthammer, Patrick (23983315500)
    ;
    Simmendinger, Hannes (57897933000)
    ;
    Kieffer, Donald (57897456500)
    ;
    Berutti, Riccardo (24483074500)
    ;
    Tasic, Velibor (7003911066)
    ;
    Abazi-Emini, Nora (57896737400)
    ;
    Nushi-Stavileci, Valbona (57193881397)
    ;
    Putnik, Jovana (14008113300)
    ;
    Stajic, Nataša (6602606131)
    ;
    Lungu, Adrian (35812503300)
    ;
    Gross, Oliver (21934239600)
    ;
    Renders, Lutz (6602849386)
    ;
    Heemann, Uwe (26643385000)
    ;
    Braunisch, Matthias C. (57192699344)
    ;
    Meitinger, Thomas (57215631099)
    ;
    Hoefele, Julia (57196082805)
    Disease-causing variants in COL4A3-5 are associated with type-IV-collagen-related nephropathy, a genetically and phenotypically multifaceted disorder comprising Alport syndrome (AS) and thin basement membrane nephropathy (TBMN) and autosomal, X-linked and a proposed digenic inheritance. Initial symptoms of individuals with AS are microscopic hematuria followed by proteinuria leading to kidney failure (90% on dialysis < age 40 years). In contrast, individuals with TBMN, an outdated histology-derived term, present with microscopic hematuria, only some of them develop kidney failure (>50 years of age). An early diagnosis of type-IV-collagen-related nephropathy is essential for optimized therapy and slowing of the disease. Sixty index cases, in whom exome sequencing had been performed and with disease-causing variant(s) in COL4A3-5, were evaluated concerning their clinical tentative diagnosis and their genotype. Of 60 reevaluated individuals with type-IV-collagen-related nephropathy, 72% had AS, 23% TBMN and 5% focal segmental glomerulosclerosis (FSGS) as clinical tentative diagnosis. The FSGS cases had to be re-classified as having type-IV-collagen-related nephropathy. Twelve percent of cases had AS as clinical tentative diagnosis and a monoallelic disease-causing variant in COL4A3/4 but could not be classified as autosomal dominant AS because of limited or conflicting clinical data. This study illustrates the complex clinical and genetic picture of individuals with a type IV-collagen-related nephropathy indicating the need of a refined nomenclature and the more interdisciplinary teamwork of clinicians and geneticists as the key to optimized patient care. Copyright © 2022 Ćomić, Riedhammer, Günthner, Schaaf, Richthammer, Simmendinger, Kieffer, Berutti, Tasic, Abazi-Emini, Nushi-Stavileci, Putnik, Stajic, Lungu, Gross, Renders, Heemann, Braunisch, Meitinger and Hoefele.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback